65 related articles for article (PubMed ID: 12214589)
1. The drug pipeline starts filling up again.
Susman E
AIDS; 2002 Aug; 16(12):N7. PubMed ID: 12214589
[No Abstract] [Full Text] [Related]
2. Anti-HIV agents. New drugs in the pipeline.
TreatmentUpdate; 2003; 15(2):1-3. PubMed ID: 12691045
[No Abstract] [Full Text] [Related]
3. Entry inhibitors: a primer on the class and on its most promising agents.
Shepherd JC; Quinn TC
Hopkins HIV Rep; 2004 Jul; 16(4):1-4, 11. PubMed ID: 15386834
[No Abstract] [Full Text] [Related]
4. Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro.
Pang W; Wang RR; Yang LM; Liu CM; Tien P; Zheng YT
Virology; 2008 Jul; 377(1):80-7. PubMed ID: 18499209
[TBL] [Abstract][Full Text] [Related]
5. Korean medicinal plants inhibiting to human immunodeficiency virus type 1 (HIV-1) fusion.
Chang YS; Woo ER
Phytother Res; 2003 Apr; 17(4):426-9. PubMed ID: 12722157
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 entry and how to block it.
Brelot A; Alizon M
AIDS; 2001; 15 Suppl 5():S3-11. PubMed ID: 11816172
[No Abstract] [Full Text] [Related]
7. CCR5 antagonists as anti-HIV-1 agents. Part 2: Synthesis and biological evaluation of N-[3-(4-benzylpiperidin-1-yl)propyl]-N,N'-diphenylureas.
Imamura S; Kurasawa O; Nara Y; Ichikawa T; Nishikawa Y; Iida T; Hashiguchi S; Kanzaki N; Iizawa Y; Baba M; Sugihara Y
Bioorg Med Chem; 2004 May; 12(9):2295-306. PubMed ID: 15080927
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and evaluation of potential inhibitors of HIV gp120-CD4 interactions.
Boussard C; Klimkait T; Mahmood N; Pritchard M; Gilbert IH
Bioorg Med Chem Lett; 2004 May; 14(10):2673-6. PubMed ID: 15109676
[TBL] [Abstract][Full Text] [Related]
9. Prospects of HIV-1 entry inhibitors as novel therapeutics.
Pierson TC; Doms RW; Pöhlmann S
Rev Med Virol; 2004; 14(4):255-70. PubMed ID: 15248253
[TBL] [Abstract][Full Text] [Related]
10. Ceramide, a target for antiretroviral therapy.
Finnegan CM; Rawat SS; Puri A; Wang JM; Ruscetti FW; Blumenthal R
Proc Natl Acad Sci U S A; 2004 Oct; 101(43):15452-7. PubMed ID: 15489273
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 gp41: mediator of fusion and target for inhibition.
Weiss CD
AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
[TBL] [Abstract][Full Text] [Related]
12. Multidrug-resistant HIV-1.
Tayloe D
Clin Infect Dis; 2004 May; 38(10):1507; author reply 1507. PubMed ID: 15156500
[No Abstract] [Full Text] [Related]
13. Experimental and clinical research of HIV-1 resistance in three AIDS patients who had experienced multiple regimens.
Lu JF; Li J; Li HP; Liu SY; Zhuang DM; Liu YJ; Bao ZY; Li L; Wu H; Li JY
Chin Med J (Engl); 2009 Mar; 122(6):752-4. PubMed ID: 19323948
[No Abstract] [Full Text] [Related]
14. [1,2,6-tri-O-galloyl-beta-D-glucopyranose inhibits gp41-mediated HIV envelope fusion with target cell membrane].
Sun W; Wang HT; Xia CL; Wu SG; Jiang SB; Jiang ZH; Liu SW
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul; 28(7):1127-31. PubMed ID: 18676243
[TBL] [Abstract][Full Text] [Related]
15. 3-O-Glutaryl-dihydrobetulin and related monoacyl derivatives as potent anti-HIV agents.
Kashiwada Y; Sekiya M; Ikeshiro Y; Fujioka T; Kilgore NR; Wild CT; Allaway GP; Lee KH
Bioorg Med Chem Lett; 2004 Dec; 14(23):5851-3. PubMed ID: 15501054
[TBL] [Abstract][Full Text] [Related]
16. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y
Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral resistance.
Geretti AM
J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
[No Abstract] [Full Text] [Related]
18. Anti-AIDS agents. Part 61: Anti-HIV activity of new podophyllotoxin derivatives.
Zhu XK; Guan J; Xiao Z; Cosentino LM; Lee KH
Bioorg Med Chem; 2004 Aug; 12(15):4267-73. PubMed ID: 15246103
[TBL] [Abstract][Full Text] [Related]
19. Changing transmission fitness of drug-resistant human immunodeficiency virus against a background of evolving antiretroviral therapy.
Murray JM
J Infect Dis; 2003 Oct; 188(8):1258; author reply 1258-9. PubMed ID: 14551898
[No Abstract] [Full Text] [Related]
20. Anti-HIV activity of some synthetic lignanolides and intermediates.
Sancho R; Medarde M; Sánchez-Palomino S; Madrigal BM; Alcamí J; Muñoz E; San Feliciano A
Bioorg Med Chem Lett; 2004 Sep; 14(17):4483-6. PubMed ID: 15357976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
